Everything about Tyrosinase-IN-12
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Principal demo targets have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patie